Early-stage health technology assessment of fractional flow reserve coronary computed tomography versus standard diagnostics in patients with stable chest pain in The Netherlands
PLOS ONE · 13.06.2024 · 19 (6) · e0305189
DOI: 10.1371/journal.pone.0305189 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 13.06.2024. Verfasst von Iris W A Boot und 3 weiteren Autor:innen. Beteiligte Einrichtung: Panaxea B.V., Den Bosch, The Netherlands. Hauptthemen laut MEDLINE: Chest Pain, Technology Assessment, Biomedical, Fractional Flow Reserve, Myocardial. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hemolens.
Abstract (Originalsprache)
Objectives
The aim of this early-stage Health Technology Assessment (HTA) was to assess the difference in healthcare costs and effects of fractional flow reserve derived from coronary computed tomography (FFRct) compared to standard diagnostics in patients with stable chest pain in The Netherlands.
Methods
A decision-tree model was developed to assess the difference in total costs from the hospital perspective, probability of correct diagnoses, and risk of major adverse cardiovascular events at one year follow-up. One-way sensitivity analyses were conducted to determine the main drivers of the cost difference between the strategies. A threshold analysis on the added price of FFRct analysis (computational analysis only) was conducted.
Results
The mean one-year costs were €2,680 per patient for FFRct and €2,915 per patient for standard diagnostics. The one-year probability of correct diagnoses was 0.78 and 0.61, and the probability of major adverse cardiovascular events was 1.92x10 -5 and 0.01, respectively. The probability and costs of revascularization and the specificity of coronary computed tomography angiography had the greatest effect on the difference in costs between the strategies. The added price of FFRct analysis should be below €935 per patient to be considered the least costly option.
Conclusions
The early-stage HTA findings suggest that FFRct may reduce total healthcare spending, probability of incorrect diagnoses, and major adverse cardiovascular events compared to current diagnostics for patients with stable chest pain in the Dutch healthcare setting over one year. Future cost-effectiveness studies should determine a value-based pricing for FFRct and quantify the economic value of the anticipated therapeutic impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Panaxea B.V., Den Bosch, The Netherlands.
- Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.
- Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
- Department of Cardiology, Amsterdam UMC - Location AMC, University of Amsterdam, Amsterdam, The Netherlands.
ORCID-Profile: Iris W A Boot, R Nils Planken
Förderung
- Hemolens
Zitieren
APA
Boot, I. W. A., Planken, R. N., den Hartog, A. W., & Vrijhoef, H. J. M. (2024). Early-stage health technology assessment of fractional flow reserve coronary computed tomography versus standard diagnostics in patients with stable chest pain in The Netherlands. PLOS ONE, 19(6), e0305189. https://doi.org/10.1371/journal.pone.0305189
Vancouver
Boot IWA, Planken RN, den Hartog AW, Vrijhoef HJM. Early-stage health technology assessment of fractional flow reserve coronary computed tomography versus standard diagnostics in patients with stable chest pain in The Netherlands. PLOS ONE. 2024;19(6):e0305189. doi:10.1371/journal.pone.0305189
BibTeX
@article{Boot2024,
author = {Boot, Iris W A and Planken, R Nils and den Hartog, Alexander W and Vrijhoef, Hubertus J M},
title = {Early-stage health technology assessment of fractional flow reserve coronary computed tomography versus standard diagnostics in patients with stable chest pain in The Netherlands},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {6},
pages = {e0305189},
doi = {10.1371/journal.pone.0305189}
}
EUVIMED